Screener
Immix Biopharma, Inc. IMMX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $79,250,163 | $93,928,566 |
| Short-term investments | 11,328,999 | 6,480,860 |
| Prepaid expenses and other current assets | 1,695,649 | 828,329 |
| Total current assets | 92,274,811 | 101,237,755 |
| Other assets | 20,418 | 20,418 |
| Deferred offering costs | 164,723 | 93,630 |
| Right-of-use asset, net | 927,728 | 966,917 |
| Property and equipment, net | 2,428,377 | 2,521,621 |
Document
FAQ
- What is Immix Biopharma, Inc.'s total current assets?
- Immix Biopharma, Inc. (IMMX) reported total current assets of $92.27M in Q1 2026.
- How has Immix Biopharma, Inc.'s total current assets changed year-over-year?
- Immix Biopharma, Inc.'s total current assets increased by 449.9% year-over-year, from $16.78M to $92.27M.
- What is the long-term trend for Immix Biopharma, Inc.'s total current assets?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total current assets has grown at a 185.7% compound annual growth rate (CAGR), from $532.24K to $101.24M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Immix Biopharma, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude